Claims for Patent: 9,752,138

Summary for Patent: 9,752,138

Title:	Methods and apparatuses for isolating and preparing stem cells
Abstract:	The present invention relates to a method of preparing a population of stem cells for autologous implantation to a subject. The cells are activated by irradiating the cells with one or more wavelengths of yellow and red and/or green light. In particular, the cells are irradiated with 575-595 nm (5-20 mW), and 630-635 nm or 660-670 nm (10-100 mW) and/or 510-540 nm (10-60 mW) of monochromatic light for 30-60 mins. Preferably the stem cells are adipose-derived stem cells. Also the invention relates to therapeutic applications of the activated stem cells.
Inventor(s):	Paspaliaris; Bill (Victoria, AU), Thornton; James Andrew Farrant (Makati, PH)
Assignee:	ADISTEM LTD. (Wanchai, HK)
Application Number:	14/045,828
Patent Claims:	1. A method of preparing a population of adipose-derived stem cells (ADSC) for autologous implantation to a subject, comprising: (i) collecting adipose tissue and blood from a subject, (ii) isolating ADSCs cells from the adipose tissue and platelet rich plasma (PRP) from the blood, (iii) activating the isolated ADSCs by irradiation with yellow light at a wavelength of 575-595 nm and at 5-20 mW, red light at wavelength of 630-635 nm and at 10-100 mW, and green light at a wavelength of 510-540 nm and at 10-60 mW, for 30-60 minutes, (iv) mixing the activated ADSCs with the PRP, thereby preparing a population of ADSCs for autologous implantation. 2. The method of claim 1, wherein the ADSCs are irradiated with yellow light at a wavelength of 595 nm and at 20 mW, red light at wavelength of 635 nm and at 60 mW, and green light at a wavelength of 535 nm and at 60 mW, for 30-60 minutes. 3. The method of claim 1, wherein the isolated ADSCs in step (ii) are exposed to one or more growth factors. 4. The method of claim 3 wherein the growth factors are Epidermal Growth Factor (EGF); Platelet-Derived Growth Factor (PDGF); Fibroblast Growth Factor (FGF); Transforming Growth Factor-.beta. (TGF-.beta.); Erythropoietin (EPO); Insulin-like Growth Factor-I (IGF-I); Insulin-like Growth Factor-II; and/or Tumor Necrosis Factor-.alpha. (TNF-.alpha.). 5. The method of claim 3 wherein the PRP comprises one or more growth factors. 6. The method of claim 1, wherein step (i) comprises exposing the adipose tissue to a lipid dissolving agent. 7. The method of claim 6 wherein said lipid dissolving agent is lecithin. 8. The method of claim 1, wherein step (i) comprises exposing the adipose tissue to collagenase. 9. The method of claim 1, wherein the adipose tissue is isolated from the subject by liposuction and/or lipoplasty. 10. The method of claim 1 comprising: i) processing the sample of adipose tissue from the subject to obtain a concentrated population of ADSC, said processing comprising: removing free lipid and single cell components of the tissue by rinsing; disaggregating the tissue using mechanical forces, collagenase and lecithin digestion, separating and concentrating the ADSC using centrifugation; and ii) activating the population of ADSC by irradiating the cells with yellow light at a wavelength of 575-595 nm and at 5-20 mW, red light at wavelength of 630-635 nm and at 10-100 mW, and green light at a wavelength of 510-540 nm and at 10-60 mW, for 30-60 mins, and incubating the ADSCs in the presence of PRP prepared from the patient to be treated at 30.degree. C. to 38.degree. C. for 5-120 minutes.

Details for Patent 9,752,138

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2029-04-30